- Trials with a EudraCT protocol (179)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
179 result(s) found for: Pegylated interferon.
Displaying page 7 of 9.
EudraCT Number: 2013-000636-10 | Sponsor Protocol Number: GS-US-320-0110 | Start Date*: 2013-11-21 | |||||||||||
Sponsor Name:Gilead Sciences Inc | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012000-10 | Sponsor Protocol Number: MK-7009, 019 | Start Date*: 2009-07-13 | |||||||||||
Sponsor Name:Merck Sharp & Dohme (Europe) Inc. | |||||||||||||
Full Title: A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-7009 When Administered Concomitantly with Pegylated Interferon and Rib... | |||||||||||||
Medical condition: Chronic hepatitis C infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004928-35 | Sponsor Protocol Number: VX-950HPC3008 | Start Date*: 2012-02-29 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects with Ge... | |||||||||||||
Medical condition: Chronic hepatitis C infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000150-12 | Sponsor Protocol Number: 7009 | Start Date*: 2009-09-07 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and ... | |||||||||||||
Medical condition: Chronic hepatitis C infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) SE (Completed) DE (Completed) BE (Completed) GB (Prematurely Ended) CZ (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003533-41 | Sponsor Protocol Number: 1241.20 | Start Date*: 2012-12-04 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A Phase III, Randomised, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination with Faldaprevir and Ribavirin in Treatment-Naïve Patients with Chronic Genotype 1 HCV Infec... | |||||||||||||
Medical condition: Chronic infection with HCV - genotype 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PT (Completed) GB (Completed) ES (Completed) IE (Completed) IT (Completed) NL (Completed) HU (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004905-29 | Sponsor Protocol Number: TMC435HPC3014 | Start Date*: 2013-08-19 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 plus Pegylated Interferon alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects with Chro... | |||||||||||||
Medical condition: Hepatitis C Virus (HCV) genotype-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) AT (Completed) IT (Completed) ES (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003167-54 | Sponsor Protocol Number: EIG-LNF-011 | Start Date*: 2019-06-24 | |||||||||||
Sponsor Name:Eiger BioPharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared... | |||||||||||||
Medical condition: The proposed indication for lonafarnib coadministered with ritonavir is for the treatment of chronic HDV infection. Approximately 5% of HBV-infected individuals are infected with HDV worldwide. Ch... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) BG (Completed) GR (Completed) ES (Ongoing) SE (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003006-16 | Sponsor Protocol Number: 5172-079 | Start Date*: 2017-12-19 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to less than 18 Years with Chro... | |||||||||||||
Medical condition: Chronic genotype 1 or genotype 4 Hepatitis C Virus infection | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) PL (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004974-82 | Sponsor Protocol Number: 2013.837 | Start Date*: 2014-04-04 | ||||||||||||||||
Sponsor Name:Hospices Civils de Lyon | ||||||||||||||||||
Full Title: PETALS study : PEgylated interferon-alpha2a and TAsigna® for first Line therapy of Philadelphia chromosome-positive chronic phase CML patientS | ||||||||||||||||||
Medical condition: Chronic phase chronic myeloid leukaemia with Philadelphia chromosome positive or BCR-ABL positive | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002979-35 | Sponsor Protocol Number: 209348 | Start Date*: 2020-12-22 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment with GSK3228836 followed by Pegylated Interferon Alpha 2a in Participants with Chron... | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004978-26 | Sponsor Protocol Number: 73763989PAHPB2005 | Start Date*: 2020-10-12 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, randomized, open-label, multicenter study to evaluate efficacy, pharmacokinetics, safety, and tolerability of response-guided treatment with JNJ-73763989 + JNJ-56136379 + nucleos(t)ide a... | |||||||||||||
Medical condition: Chronic Hepatitis B Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001804-12 | Sponsor Protocol Number: ISA-HPV-01-12 | Start Date*: 2016-12-01 | |||||||||||
Sponsor Name:ISA Therapeutics B.V. | |||||||||||||
Full Title: A multicenter, open label Phase I/II study to determine the safety and immune modulating effects of the therapeutic Human Papilloma Virus Type 16 (HPV16) E6/E7 Synthetic Long Peptides Vaccine (ISA1... | |||||||||||||
Medical condition: Patients with advanced (Stage IIIb-IVa with involvement of lymph nodes beyond the renal vein) or metastatic (stage IVb) or recurrent HPV16 positive cervical cancer for whom no curative treatment op... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009608-38 | Sponsor Protocol Number: NV21075 | Start Date*: 2010-06-14 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche | |||||||||||||
Full Title: A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Co... | |||||||||||||
Medical condition: Chronic Hepatitis C Genotype 1 Virus Infection (Treatment-Naive Patients) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000944-43 | Sponsor Protocol Number: GS-US-248-0120 | Start Date*: 2011-08-09 | ||||||||||||||||
Sponsor Name:Gilead Sciences Inc. | ||||||||||||||||||
Full Title: A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly with GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Genotype 1 HCV Infection | ||||||||||||||||||
Medical condition: Genotype 1 Hepatitis C Virus Infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-021337-31 | Sponsor Protocol Number: TMC435-TiDP16-C212 | Start Date*: 2011-11-03 | |||||||||||
Sponsor Name:Janssen R&D Ireland | |||||||||||||
Full Title: A Phase III open-label study to evaluate the safety, tolerability and efficacy of TMC435 plus PegIFNα-2a (Pegasys) and ribavirin (Copegus) triple therapy in chronic hepatitis C genotype-1 infected ... | |||||||||||||
Medical condition: Hepatitis C and co-infected with HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003956-34 | Sponsor Protocol Number: 73763989PAHPB2006 | Start Date*: 2021-01-16 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analogs, and Pegylate... | |||||||||||||
Medical condition: Chronic Hepatitis B Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005293-31 | Sponsor Protocol Number: AI452-016 | Start Date*: 2012-06-01 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C Revised Proto... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) ES (Completed) PL (Completed) IT (Completed) GR (Completed) FI (Completed) BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000141-20 | Sponsor Protocol Number: 1220.48 | Start Date*: 2011-07-12 | |||||||||||
Sponsor Name:Boehringer Ingelheim Limited | |||||||||||||
Full Title: A phase III, open-label study of once daily BI 201335 240 mg for 24 weeks in combination with pegylated interferon-α (PegIFN) and ribavirin (RBV) in patients with genotype 1 chronic hepatitis C inf... | |||||||||||||
Medical condition: Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) DE (Completed) AT (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000785-37 | Sponsor Protocol Number: GS-US-320-1092 | Start Date*: 2016-08-26 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA BE (Completed) IT (Prematurely Ended) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001283-37 | Sponsor Protocol Number: GE-ARNICA-2008 | Start Date*: 2007-09-24 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: Chronic hepatitis C in illicit drug users and the role of antiviral therapy: the ARNICA project (Antiviral tReatment for chroNic hepatItis C in Active substance users) | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
